Hospital
El Centro Regional Medical Center
El Centro Regional Medical Center was paid $49.37M by Medicaid between Jan 2018 and Nov 2024, across 440 billing codes. Its largest line is 0450, Emergency room services — 10% of everything it billed.
33Billing provider infoEL CENTRO REGIONAL MEDICAL CENTER
EL CENTRO, CA 92243
EL CENTRO, CA 92243
33aNPI1861409823assigned 08/02/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$49.37M
24GClaims2,206,857
24DCodes billed440
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#61 of 410
Median peer was paid$6.90M
This provider vs. median7.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 374,202 | $8.02M | |
| 2019 | 384,894 | $9.28M | |
| 2020 | 274,911 | $6.43M | |
| 2021 | 291,438 | $6.55M | |
| 2022 | 303,494 | $6.90M | |
| 2023 | 332,651 | $6.53M | |
| 2024incomplete | 245,267 | $5.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 10% | 97,889 | 86,182 | $5.08M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 7.2% | 8,504 | 8,151 | $3.53M |
| 80053 | Comprehensive metabolic panel | 3.3% | 164,563 | 148,795 | $1.61M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 8,279 | 7,872 | $1.46M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.6% | 51,423 | 50,946 | $1.26M |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.1% | 24,097 | 22,747 | $1.06M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.1% | 4,684 | 4,552 | $1.02M |
| 84443 | Thyroid stimulating hormone (TSH) | 2.1% | 68,761 | 67,258 | $1.02M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 166,970 | 147,067 | $1.01M |
| 87507 | 1.9% | 2,456 | 2,394 | $959K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.7% | 9,870 | 9,849 | $850K |
| 86480 | 1.7% | 19,685 | 19,548 | $834K |
428 more codes
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.7% | 12,127 | $829K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 15,004 | $782K |
| 0250 | 1.6% | 34,690 | $772K | |
| 80061 | Lipid panel | 1.5% | 73,968 | $747K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 12,665 | $686K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 8,166 | $682K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 31,786 | $666K |
| 99499 | 1.3% | 11,641 | $625K | |
| G9012 | Other specified case management service not elsewhere classified | 1.2% | 3,500 | $609K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 15,108 | $547K |
| 99284 | Emergency room visit (serious) | 1.0% | 7,730 | $505K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.0% | 13,908 | $504K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.0% | 14,432 | $501K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.0% | 14,460 | $500K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 14,591 | $488K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 57,374 | $484K |
| 99283 | Emergency room visit (moderate) | <1% | 7,730 | $482K |
| 0270 | <1% | 42,701 | $419K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 21,292 | $411K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,727 | $405K |
| 87486 | <1% | 8,329 | $368K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,787 | $367K |
| 87581 | <1% | 8,328 | $365K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,907 | $358K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 19,731 | $333K |
| 76641 | <1% | 5,086 | $321K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 394 | $319K |
| 0762 | <1% | 5,818 | $314K | |
| 87088 | <1% | 45,180 | $301K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 3,503 | $290K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,307 | $288K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,874 | $285K |
| 76830 | Ultrasound, transvaginal | <1% | 4,537 | $282K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 72 | $276K |
| 0360 | <1% | 2,000 | $264K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,986 | $254K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,241 | $252K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,876 | $251K |
| 81000 | <1% | 99,316 | $251K | |
| G9008 | Coordinated care fee, physician coordinated care oversight services | <1% | 711 | $242K |
| 99285 | Emergency room visit (most serious) | <1% | 2,147 | $241K |
| 80074 | <1% | 4,880 | $224K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,386 | $224K |
| 96367 | <1% | 7,382 | $221K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,028 | $218K |
| 71045 | Radiologic examination, chest; single view | <1% | 24,301 | $208K |
| 76770 | <1% | 3,662 | $207K | |
| 0761 | <1% | 6,565 | $192K | |
| 93970 | <1% | 1,292 | $176K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 7,565 | $176K |
| 84484 | <1% | 21,802 | $170K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 7,664 | $169K |
| J0897 | Injection, denosumab, 1 mg | <1% | 338 | $168K |
| 87070 | <1% | 20,499 | $166K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 10,312 | $153K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 19,296 | $145K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,356 | $140K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,159 | $139K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,183 | $135K |
| 73562 | <1% | 6,094 | $132K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,917 | $132K |
| 93971 | <1% | 1,431 | $131K | |
| 72110 | <1% | 3,485 | $131K | |
| 83880 | <1% | 6,139 | $130K | |
| 76536 | <1% | 2,655 | $125K | |
| 83690 | <1% | 20,399 | $123K | |
| 87400 | <1% | 15,248 | $122K | |
| 93000 | <1% | 3,798 | $114K | |
| 84439 | <1% | 13,867 | $112K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,266 | $111K |
| 73630 | <1% | 4,881 | $111K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,227 | $109K |
| 76801 | <1% | 2,010 | $108K | |
| G0378 | Hospital observation service, per hour | <1% | 3,597 | $107K |
| 0710 | <1% | 4,693 | $103K | |
| 83525 | <1% | 10,320 | $101K | |
| 73030 | <1% | 4,591 | $100K | |
| 87186 | <1% | 13,550 | $98K | |
| 85027 | <1% | 15,055 | $97K | |
| 82043 | <1% | 20,603 | $97K | |
| 82607 | <1% | 6,890 | $96K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,150 | $95K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 522 | $92K |
| 90715 | <1% | 2,466 | $90K | |
| Q3014 | Telehealth originating site facility fee | <1% | 8,744 | $90K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,255 | $87K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,944 | $87K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,979 | $85K |
| 74018 | <1% | 5,783 | $85K | |
| 87077 | <1% | 14,697 | $84K | |
| 73610 | <1% | 3,312 | $82K | |
| 73130 | <1% | 3,148 | $82K | |
| 86780 | <1% | 7,663 | $76K | |
| Z7502 | <1% | 2,862 | $75K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 716 | $73K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 5,501 | $73K |
| 81025 | <1% | 10,131 | $71K | |
| 83970 | <1% | 3,217 | $70K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 1,538 | $70K |
| 82570 | <1% | 19,249 | $69K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,186 | $69K |
| 85730 | <1% | 14,110 | $68K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 419 | $67K |
| 74178 | <1% | 478 | $66K | |
| 87040 | <1% | 5,218 | $64K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,641 | $64K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,739 | $60K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 349 | $59K |
| 73502 | <1% | 2,296 | $59K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,127 | $59K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,475 | $59K |
| 87205 | <1% | 15,774 | $57K | |
| 76870 | <1% | 1,195 | $57K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,932 | $56K |
| 73110 | <1% | 2,278 | $55K | |
| 77065 | Tomosynthesis, mammo | <1% | 874 | $55K |
| 72100 | <1% | 2,076 | $54K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 156 | $54K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,814 | $53K |
| 85610 | <1% | 17,478 | $52K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,025 | $50K |
| 96415 | <1% | 2,096 | $50K | |
| 70498 | <1% | 543 | $49K | |
| 84153 | <1% | 2,994 | $49K | |
| 0720 | <1% | 847 | $49K | |
| 77080 | <1% | 2,309 | $49K | |
| 70496 | <1% | 455 | $48K | |
| 83605 | <1% | 5,166 | $47K | |
| 82962 | <1% | 13,662 | $47K | |
| 86140 | <1% | 10,491 | $47K | |
| 93880 | <1% | 428 | $45K | |
| 72050 | <1% | 1,453 | $45K | |
| 70486 | <1% | 371 | $43K | |
| 83540 | <1% | 8,985 | $42K | |
| 86703 | <1% | 2,971 | $42K | |
| 71250 | <1% | 625 | $42K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 150 | $41K |
| 82746 | <1% | 3,138 | $41K | |
| Z9725 | <1% | 1,356 | $41K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,095 | $40K |
| 86235 | <1% | 2,348 | $40K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,776 | $39K |
| 76775 | <1% | 1,287 | $39K | |
| 72131 | <1% | 405 | $38K | |
| 73560 | <1% | 1,961 | $38K | |
| 83735 | <1% | 7,618 | $37K | |
| 83550 | <1% | 7,142 | $37K | |
| 0760 | <1% | 1,059 | $37K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,669 | $37K |
| 76881 | <1% | 986 | $37K | |
| 84702 | <1% | 2,859 | $36K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 134 | $35K |
| 84480 | <1% | 3,687 | $35K | |
| 82728 | <1% | 5,616 | $35K | |
| 96417 | <1% | 1,549 | $32K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 920 | $31K |
| 73080 | <1% | 1,265 | $31K | |
| 82550 | <1% | 5,311 | $31K | |
| 84550 | <1% | 9,441 | $31K | |
| 73590 | <1% | 1,477 | $30K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,831 | $30K |
| 84436 | <1% | 5,215 | $30K | |
| 72070 | <1% | 1,248 | $29K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,313 | $29K |
| 86038 | <1% | 3,624 | $28K | |
| 87210 | <1% | 6,192 | $27K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 326 | $27K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 621 | $27K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 321 | $26K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 130 | $26K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,212 | $25K |
| 85378 | <1% | 3,991 | $25K | |
| 87653 | <1% | 776 | $24K | |
| 73090 | <1% | 1,297 | $24K | |
| 96523 | <1% | 1,020 | $23K | |
| 59025 | Fetal non-stress test | <1% | 1,087 | $23K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 410 | $22K |
| 85651 | <1% | 10,466 | $22K | |
| 86431 | <1% | 4,021 | $21K | |
| 86376 | <1% | 2,060 | $21K | |
| 86922 | <1% | 398 | $20K | |
| 86803 | <1% | 1,512 | $20K | |
| 80069 | <1% | 3,599 | $19K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,373 | $19K |
| 84481 | <1% | 1,795 | $19K | |
| 87522 | Neg quan hep c or qual rna | <1% | 384 | $19K |
| 94060 | <1% | 565 | $19K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 75 | $19K |
| 86901 | <1% | 6,449 | $18K | |
| 80076 | <1% | 2,882 | $18K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 459 | $18K |
| 84703 | <1% | 2,406 | $17K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,585 | $17K |
| 87340 | <1% | 1,541 | $17K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 312 | $17K |
| 87420 | <1% | 3,245 | $17K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,925 | $16K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 65 | $16K |
| 73140 | <1% | 917 | $16K | |
| 72170 | <1% | 1,008 | $16K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 938 | $16K |
| 82274 | <1% | 1,356 | $16K | |
| 86592 | <1% | 3,610 | $15K | |
| 82270 | <1% | 4,534 | $15K | |
| 74019 | <1% | 688 | $15K | |
| 86850 | <1% | 4,898 | $15K | |
| 85018 | <1% | 6,793 | $14K | |
| 72040 | <1% | 644 | $14K | |
| 86003 | <1% | 287 | $14K | |
| 87147 | <1% | 3,254 | $13K | |
| 73620 | <1% | 707 | $13K | |
| 86225 | <1% | 1,138 | $13K | |
| 83516 | <1% | 1,361 | $13K | |
| 84156 | <1% | 5,734 | $13K | |
| 83655 | <1% | 2,597 | $13K | |
| 86762 | <1% | 972 | $13K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,004 | $12K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 3,983 | $12K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,769 | $12K |
| 86900 | <1% | 5,216 | $11K | |
| 36430 | <1% | 97 | $11K | |
| 84100 | <1% | 3,888 | $11K | |
| 83001 | <1% | 1,159 | $11K | |
| 0004A | <1% | 274 | $11K | |
| 96376 | <1% | 232 | $11K | |
| 82785 | <1% | 549 | $11K | |
| 82803 | <1% | 1,093 | $11K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,915 | $11K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 97 | $10K |
| 84403 | <1% | 1,303 | $10K | |
| 82378 | <1% | 801 | $10K | |
| 87081 | <1% | 1,628 | $10K | |
| 87045 | <1% | 1,087 | $10K | |
| 83002 | <1% | 1,008 | $10K | |
| 86160 | <1% | 1,123 | $9K | |
| 85007 | <1% | 4,027 | $9K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 217 | $9K |
| 10060 | <1% | 472 | $9K | |
| 0001A | <1% | 262 | $9K | |
| 86300 | <1% | 628 | $9K | |
| 0002A | <1% | 253 | $9K | |
| G0202 | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | <1% | 96 | $9K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,839 | $8K |
| J3490 | Unclassified drugs | <1% | 8,009 | $8K |
| 73120 | <1% | 453 | $8K | |
| Z7610 | <1% | 1,301 | $8K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 19 | $7K |
| 73552 | <1% | 412 | $7K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,014 | $7K |
| 82150 | <1% | 1,182 | $7K | |
| 73060 | <1% | 427 | $7K | |
| 81003 | <1% | 4,258 | $7K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 579 | $7K |
| 95819 | <1% | 94 | $6K | |
| 0064A | <1% | 159 | $6K | |
| 0071A | <1% | 154 | $6K | |
| 72082 | <1% | 136 | $6K | |
| V2632 | Posterior chamber intraocular lens | <1% | 1,810 | $6K |
| 83615 | <1% | 1,246 | $6K | |
| 85044 | <1% | 2,329 | $6K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 548 | $6K |
| 0072A | <1% | 139 | $6K | |
| 86200 | <1% | 853 | $5K | |
| 86039 | <1% | 856 | $5K | |
| 82784 | <1% | 744 | $5K | |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 13 | $5K |
| 87899 | <1% | 695 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 394 | $5K |
| 87046 | <1% | 1,738 | $5K | |
| 12011 | <1% | 83 | $5K | |
| 84681 | <1% | 369 | $5K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 84 | $5K |
| 82553 | <1% | 390 | $5K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 87 | $4K |
| 83883 | <1% | 326 | $4K | |
| 0160 | <1% | 66 | $4K | |
| 86334 | <1% | 604 | $4K | |
| 82950 | <1% | 882 | $4K | |
| Z7500 | <1% | 122 | $4K | |
| 43235 | <1% | 138 | $4K | |
| 72141 | <1% | 28 | $4K | |
| 86580 | <1% | 868 | $4K | |
| 87209 | <1% | 729 | $4K | |
| 84402 | <1% | 490 | $4K | |
| 86255 | <1% | 292 | $3K | |
| 72128 | <1% | 51 | $3K | |
| 82140 | <1% | 343 | $3K | |
| 96368 | <1% | 236 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 603 | $3K |
| 99070 | <1% | 593 | $3K | |
| 12001 | <1% | 136 | $3K | |
| 87493 | <1% | 102 | $3K | |
| 0011A | <1% | 121 | $3K | |
| 71020 | <1% | 122 | $3K | |
| 0510 | <1% | 103 | $3K | |
| 82951 | <1% | 209 | $3K | |
| 82565 | <1% | 909 | $3K | |
| 86308 | <1% | 548 | $3K | |
| 97161 | <1% | 105 | $3K | |
| 12002 | <1% | 77 | $3K | |
| 52000 | <1% | 181 | $3K | |
| 84166 | <1% | 320 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,571 | $2K |
| 66982 | <1% | 94 | $2K | |
| 51798 | <1% | 363 | $2K | |
| 90714 | <1% | 80 | $2K | |
| 84460 | <1% | 480 | $2K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 258 | $2K |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 25 | $2K |
| 86335 | <1% | 341 | $2K | |
| 84450 | <1% | 470 | $2K | |
| 57454 | <1% | 24 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 258 | $2K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 202 | $2K |
| 0012A | <1% | 76 | $2K | |
| 29125 | <1% | 144 | $2K | |
| 87177 | <1% | 722 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 632 | $2K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 314 | $2K |
| 78306 | <1% | 25 | $2K | |
| 84520 | <1% | 793 | $2K | |
| 73100 | <1% | 108 | $2K | |
| 84146 | <1% | 199 | $2K | |
| 72197 | <1% | 12 | $2K | |
| 74220 | <1% | 61 | $2K | |
| 74183 | <1% | 13 | $2K | |
| 73600 | <1% | 92 | $2K | |
| 96402 | <1% | 404 | $2K | |
| 94729 | <1% | 41 | $1K | |
| 80178 | <1% | 205 | $1K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 18 | $1K |
| 84154 | <1% | 125 | $1K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 99 | $1K |
| 82239 | <1% | 159 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 302 | $1K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 55 | $1K |
| 0636 | <1% | 143 | $1K | |
| 86787 | <1% | 84 | $1K | |
| G0204 | Diagnostic mammography, including computer-aided detection (cad) when performed; bilateral | <1% | 14 | $1K |
| 0621 | <1% | 301 | $1K | |
| 94727 | <1% | 41 | $1K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 48 | $1K |
| 72220 | <1% | 53 | $1K | |
| 93925 | <1% | 42 | $1K | |
| 82105 | <1% | 56 | $1K | |
| 82805 | <1% | 41 | $991.63 | |
| 87338 | <1% | 92 | $990.97 | |
| 70360 | <1% | 57 | $981.28 | |
| 73660 | <1% | 59 | $972.67 | |
| 98960 | <1% | 31 | $961.09 | |
| 88304 | <1% | 118 | $939.42 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 348 | $895.87 |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 82 | $891.78 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 137 | $888.11 |
| 73565 | <1% | 66 | $842.84 | |
| 80081 | <1% | 12 | $822.48 | |
| 86593 | <1% | 176 | $785.81 | |
| 85014 | <1% | 328 | $765.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 13 | $748.33 |
| 73700 | <1% | 12 | $713.80 | |
| 62323 | <1% | 16 | $713.56 | |
| 86800 | <1% | 83 | $710.26 | |
| 84145 | <1% | 68 | $704.79 | |
| 82670 | <1% | 43 | $703.58 | |
| 86141 | <1% | 69 | $668.03 | |
| 90656 | <1% | 30 | $641.88 | |
| 84155 | <1% | 290 | $613.51 | |
| 82247 | <1% | 124 | $606.74 | |
| 96521 | <1% | 119 | $598.18 | |
| 82977 | <1% | 82 | $587.60 | |
| 97116 | <1% | 85 | $576.76 | |
| 84165 | <1% | 104 | $566.15 | |
| 86705 | <1% | 27 | $557.46 | |
| 0124A | <1% | 13 | $520.00 | |
| 94644 | <1% | 29 | $517.19 | |
| 74000 | <1% | 32 | $483.49 | |
| 86305 | <1% | 26 | $476.50 | |
| 58100 | <1% | 12 | $442.57 | |
| 82248 | <1% | 119 | $422.74 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 13 | $421.25 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 34 | $418.68 |
| 73523 | <1% | 12 | $414.09 | |
| 31500 | <1% | 13 | $363.05 | |
| 94760 | <1% | 683 | $355.34 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 70 | $354.75 |
| 86403 | <1% | 27 | $345.27 | |
| 85049 | <1% | 282 | $315.73 | |
| 73070 | <1% | 12 | $294.72 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 211 | $289.20 |
| G9873 | First medicare diabetes prevention program (mdpp) core session was attended by an mdpp beneficiary under the mdpp expanded model (em). a core session is an mdpp service that: (1) is furnished by an mdpp supplier during months 1 through 6 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for core sessions | <1% | 13 | $280.79 |
| 71010 | <1% | 23 | $277.58 | |
| 83013 | <1% | 17 | $273.50 | |
| 51702 | <1% | 35 | $270.18 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 26 | $259.84 |
| 0637 | <1% | 249 | $247.46 | |
| 76882 | <1% | 28 | $232.19 | |
| 83520 | <1% | 30 | $229.37 | |
| 86021 | <1% | 19 | $219.87 | |
| 87220 | <1% | 57 | $217.94 | |
| 29515 | <1% | 12 | $191.93 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 13 | $186.18 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 28 | $180.50 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 14 | $156.22 |
| 0370 | <1% | 174 | $150.55 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 31 | $146.78 |
| 62322 | <1% | 12 | $142.66 | |
| 86765 | <1% | 14 | $136.40 | |
| 86735 | <1% | 13 | $130.97 | |
| 11045 | <1% | 101 | $114.78 | |
| 87101 | <1% | 12 | $112.86 | |
| 82627 | <1% | 12 | $87.00 | |
| 86696 | <1% | 17 | $58.24 | |
| 96411 | <1% | 17 | $55.50 | |
| 86695 | <1% | 17 | $38.36 | |
| 80320 | <1% | 174 | $24.15 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 48 | $12.62 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 0% | 423 | $0.00 |
| 0370R | 0% | 2,028 | $0.00 | |
| 0270R | 0% | 2,073 | $0.00 | |
| 0710R | 0% | 2,021 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 176 | $0.00 |
| 99221 | 0% | 64 | $0.00 | |
| 0637R | 0% | 3,667 | $0.00 | |
| 0250R | 0% | 8,391 | $0.00 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 164 | $0.00 |
| C9740 | Cystourethroscopy, with insertion of transprostatic implant; 4 or more implants | 0% | 72 | $0.00 |
| 0621R | 0% | 68 | $0.00 | |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 132 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBENAVIDEZ, TISHA (PATIENT FINANCIAL SERVICES DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| El Centro Regional Medical Center | El Centro, CA | $50.04M |
| El Centro Regional Medical Center | Calexico, CA | $27.78M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.